- Company
- Celltrion released the results of Regkirona's clinical trial
- by An, Kyung-Jin Jun 16, 2021 05:41am
- Celltrion is going to launch a global targeting of Regkirona (Regdanvimab), COVID-19 antibody treatment drug developed with its own technology. The government plans to eliminate controversy over efficacy and revitalize domestic and foreign markets through large-scale clinical trials. Celltrion held an online press conference on the morning
- Company
- The number of generics has been the lowest in 7 months
- by Chon, Seung-Hyun Jun 15, 2021 05:52am
- The number of Rx drugs' generic licences is the lowest in seven months since October last year. Recently, it was released in large numbers of generics for Atozet, but it fell back to its level shortly after the implementation of the drug price system. The proportion of consigned generics, which exceeded 80%, also fell to 50%. According to the
- Company
- Second trial on patent dispute over Bonviva
- by Kim, Jin-Gu Jun 14, 2021 05:56am
- There will be a patent dispute over the osteoporosis drug Bonviva (Ibandronate) again. It is an analysis of damages worth &8361;tens of billions by domestic companies that are selling generics for Bonviva. According to the pharmaceutical industry on the 10th, British pharmaceutical company Atnahs Pharma, which owns patents of Bonviva,
- Company
- What's the future of vaccines after COVID-19 crisis?
- by Kim, Jin-Gu Jun 14, 2021 05:56am
- The rate of vaccinations against COVID-19 is increasing, especially in major developed countries. Experts say we need to brace ourselves for the 'Corona 21' and 'Corona 22' pandemic. As there is a high possibility that the pandemic will continue every year even if the current pandemic situation ends, the whole world should respond jointly. At
- Company
- Stephen Walter, Boehringer Ingelheim's CEO, will resign
- by Eo, Yun-Ho Jun 11, 2021 05:53am
- Boehringer Ingelheim's CEO, Stephen Walter will be replaced. According to related industries, Stephen Walter, the current CEO of Boehringer Ingelheim in Korea, will resign after this month (June). The successor is now known as the head of an Austrian corporation and will be officially appointed in July. Boehringer Ingelheim Korea Corpor
- Company
- Hemlibra's reimbursement criteria to be rediscussed
- by Nho, Byung Chul Jun 11, 2021 05:53am
- Interest is rising as the Health Insurance Review and Assessment Service (HIRA) plans to call an expert advisory meeting to discuss the more effective operation of immune tolerance induction (ITI·antibody removal) therapies. At the end of this month, HIRA’s Pharmaceutical Standard Department plans to conduct deliberations to come up wit
- Company
- What is the most likely treatment for Alzheimer's?
- by Kim, Jin-Gu Jun 10, 2021 05:55am
- As Biogen's Aducanumab (Aduhel) was approved by the U.S. Food and Drug Administration (FDA) for the first time in 18 years as a treatment for Alzheimer's, competition for development of Aducanumab. Currently, Roche, Eli Lilly, Ezai, Johnson and Johnson are considered companies that have started to develop treatments for Alzheimer's. In
- Company
- Korean novel drug Leclaza may become cheaper than Tagrisso
- by Eo, Yun-Ho Jun 10, 2021 05:55am
- The daily drug cost of Korea's novel anticancer drug 'Leclaza' is expected to be set at a level that is around &8361;10,000 cheaper than ‘Tagrisso.’ Dailypharm found that the price of Yuhan Corp.’s 3rd generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Leclaza (lazertinib) was set at &8361;69,000 per e
- Company
- Former GSK GM Yoo-Seok Hong to head D&D Pharmatech
- by An, Kyung-Jin Jun 10, 2021 05:55am
- Yoo-Seok Hong, former General Manager of GSK Korea will be joining the leadership of the biotech company, D&D Pharmatech. On the 9th, D&D Pharmatech had announced that the company has appointed Yoo-Seok Hong as its new CEO. Hong is a seasoned expert with extensive experience in marketing and business management at multinational pharmaceut
- Company
- Once again, the fear of impurities
- by Chon, Seung-Hyun Jun 10, 2021 05:55am
- Fear of impurities is spreading again in the domestic pharmaceutical industry. There is a high risk that the aftermath of large-scale withdrawal of impurities from Canada will also damage Korea. Pharmaceutical companies are nervous in that it is a new type of impurity that is different from the one that has built a verification system over the p
